NTRK1 and hepatocellular carcinoma: Since LSF promotes both primary tumors and metastasis FQIs might be useful for treating advanced metastatic HCC either alone or in combination with receptor tyrosine kinase inhibitors, such as sorafenib, thereby providing dual pronged attack for successful elimination of the disease.